ZA200509319B - Quinoline derivatives as phosphodiesterase inhibitors - Google Patents

Quinoline derivatives as phosphodiesterase inhibitors

Info

Publication number: ZA200509319B
Authority: ZA; South Africa
Prior art keywords: phosphodiesterase inhibitors; quinoline derivatives; quinoline; derivatives; phosphodiesterase
Prior art date: 2003-05-21

Application number

ZA200509319A

Other languages

English (en)

Inventor

Baldwin Ian Robert

Dean Anthony William

Evans Brian

Guntrip Stephen Barry

Holman Stuart

Lindvall Mika Kristian

Redfern Tracy Jane

Robinson John Edward

Barker Michael David

Eldred Colin David

Gough Sharon Lisa

Hamblin Julie Nicole

Jones Paul

Alison Judith Redgrave

Christopher James Luniss

Woodrow Michael

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-05-21

Filing date

2005-11-17

Publication date

2007-02-28

2003-05-21 Priority claimed from GB0311688A external-priority patent/GB0311688D0/en

2003-11-10 Priority claimed from GB0326187A external-priority patent/GB0326187D0/en

2005-11-17 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2007-02-28 Publication of ZA200509319B publication Critical patent/ZA200509319B/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Quinoline Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

ZA200509319A 2003-05-21 2005-11-17 Quinoline derivatives as phosphodiesterase inhibitors ZA200509319B (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB0311688A GB0311688D0 (en)	2003-05-21	2003-05-21	Compounds
GB0326187A GB0326187D0 (en)	2003-11-10	2003-11-10	Compounds

Publications (1)

Publication Number	Publication Date
ZA200509319B true ZA200509319B (en)	2007-02-28

Family

ID=33477765

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200509319A ZA200509319B (en)	2003-05-21	2005-11-17	Quinoline derivatives as phosphodiesterase inhibitors

Country Status (31)

Country	Link
US (4)	US7566786B2 (el)
EP (2)	EP1944305B1 (el)
JP (1)	JP4625460B2 (el)
KR (1)	KR101144548B1 (el)
CN (1)	CN1823063B (el)
AR (1)	AR044401A1 (el)
AT (2)	ATE529421T1 (el)
AU (1)	AU2004240759B2 (el)
BR (1)	BRPI0410477A (el)
CA (1)	CA2526228C (el)
CO (1)	CO5700780A2 (el)
CY (2)	CY1108094T1 (el)
DE (1)	DE602004012260T2 (el)
DK (2)	DK1633748T3 (el)
EG (1)	EG24774A (el)
ES (2)	ES2374850T3 (el)
HK (2)	HK1092458A1 (el)
HR (2)	HRP20080236T3 (el)
IL (1)	IL171726A (el)
IS (1)	IS2581B (el)
MA (1)	MA27808A1 (el)
MX (1)	MXPA05012466A (el)
NO (1)	NO330754B1 (el)
NZ (1)	NZ543554A (el)
PL (2)	PL1944305T3 (el)
PT (2)	PT1633748E (el)
RU (1)	RU2335493C2 (el)
SI (2)	SI1944305T1 (el)
TW (1)	TWI328009B (el)
WO (1)	WO2004103998A1 (el)
ZA (1)	ZA200509319B (el)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0316290D0 (en)	2003-07-11	2003-08-13	Glaxo Group Ltd	Novel compounds
GB0411056D0 (en)	2004-05-18	2004-06-23	Novartis Ag	Organic compounds
AR049384A1 (es)	2004-05-24	2006-07-26	Glaxo Group Ltd	Derivados de purina
GB0425572D0 (en) *	2004-11-19	2004-12-22	Glaxo Group Ltd	1,7-Naphthyridines
ATE517908T1 (de)	2005-01-10	2011-08-15	Glaxo Group Ltd	Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände
GB0503955D0 (en) *	2005-02-25	2005-04-06	Glaxo Group Ltd	Novel compounds
GB0505621D0 (en) *	2005-03-18	2005-04-27	Glaxo Group Ltd	Novel compounds
GB0514809D0 (en)	2005-07-19	2005-08-24	Glaxo Group Ltd	Compounds
AU2006287521A1 (en) *	2005-09-07	2007-03-15	Plexxikon, Inc.	PPARactive compounds
GB0521563D0 (en)	2005-10-21	2005-11-30	Glaxo Group Ltd	Novel compounds
PE20071068A1 (es)	2005-12-20	2007-12-13	Glaxo Group Ltd	Acido 3-(4-{[4-(4-{[3-(3,3-dimetil-1-piperidinil)propil]oxi}fenil)-1-piperidinil]carbonil}-1-naftalenil)propanoico o propenoico, sales de los mismos, como antagonistas de los receptores h1 y h3
GB0601951D0 (en)	2006-01-31	2006-03-15	Novartis Ag	Organic compounds
NZ570844A (en)	2006-02-28	2011-11-25	Helicon Therapeutics Inc	Therapeutic piperazines as PDE4 inhibitors
US8927546B2 (en)	2006-02-28	2015-01-06	Dart Neuroscience (Cayman) Ltd.	Therapeutic piperazines
US20070299067A1 (en) *	2006-03-08	2007-12-27	Ruiping Liu	Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors
GB0605462D0 (en) *	2006-03-17	2006-04-26	Glaxo Group Ltd	Novel compounds
AR060536A1 (es)	2006-04-20	2008-06-25	Glaxo Group Ltd	Agonista del receptor de glucocorticoides y composiciones farmaceuticas
CA2650683A1 (en) *	2006-04-28	2007-11-08	Shionogi & Co., Ltd.	Amine derivative having npy y5 receptor antagonist activity
GB0611587D0 (en)	2006-06-12	2006-07-19	Glaxo Group Ltd	Novel compounds
TW200817006A (en)	2006-06-23	2008-04-16	Smithkline Beecham Corp	IL-8 receptor antagonist
KR20090075714A (ko)	2006-10-30	2009-07-08	노파르티스 아게	소염제로서의 헤테로시클릭 화합물
TW200829555A (en) *	2006-11-10	2008-07-16	Astrazeneca Ab	Chemical compounds
PE20081889A1 (es)	2007-03-23	2009-03-05	Smithkline Beecham Corp	Indol carboxamidas como inhibidores de ikk2
PT2231642E (pt)	2008-01-11	2014-03-12	Novartis Ag	Pirimidinas como inibidores de quinase
EP2285803A4 (en)	2008-05-23	2011-10-05	Amira Pharmaceuticals Inc	Inhibitor of 5-Lipoxygenase Activating Protein
US8163743B2 (en)	2008-06-05	2012-04-24	GlaxoGroupLimited	4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases
US8729097B2 (en)	2008-10-06	2014-05-20	The Johns Hopkins University	Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and SIRT1, and methods of treating disorders
JP2012513464A (ja) *	2008-12-23	2012-06-14	ザトラスティーズオブコロンビアユニヴァーシティインザシティオブニューヨーク	ホスホジエステラーゼ阻害剤及びその使用
BRPI1006162A2 (pt)	2009-01-13	2019-09-24	Glaxo Group Ltd	"composto,processo para preparar um composto,formulação farmacêutica,e uso de um composto".
WO2010094643A1 (en)	2009-02-17	2010-08-26	Glaxo Group Limited	Quinoline derivatives and their uses for rhinitis and urticaria
WO2010102958A1 (en)	2009-03-09	2010-09-16	Glaxo Group Limited	4-oxadiazol-2 -yl- indazoles as inhibitors of p13 kinases
WO2010102968A1 (en)	2009-03-10	2010-09-16	Glaxo Group Limited	Indole derivatives as ikk2 inhibitors
WO2010106016A1 (en)	2009-03-17	2010-09-23	Glaxo Group Limited	Pyrimidine derivatives used as itk inhibitors
JP2012520684A (ja)	2009-03-19	2012-09-10	メルク・シャープ・エンド・ドーム・コーポレイション	低分子干渉核酸（ｓｉＮＡ）を用いたＢＴＢａｎｄＣＮＣＨｏｍｏｌｏｇｙ１（塩基性ロイシンジッパー転写因子１）（Ｂａｃｈ１）遺伝子発現のＲＮＡ干渉媒介性阻害
EP2408916A2 (en)	2009-03-19	2012-01-25	Merck Sharp&Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2408458A1 (en)	2009-03-19	2012-01-25	Merck Sharp&Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2408915A2 (en)	2009-03-19	2012-01-25	Merck Sharp&Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
KR20110138223A (ko)	2009-03-27	2011-12-26	머크 샤프 앤드 돔 코포레이션	짧은 간섭 핵산 (ｓｉＮＡ)을 사용한 세포간 부착 분자 1 (ＩＣＡＭ-1) 유전자 발현의 ＲＮＡ 간섭 매개 억제
EP2411520A2 (en)	2009-03-27	2012-02-01	Merck Sharp&Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20120004281A1 (en)	2009-03-27	2012-01-05	Merck Sharp & Dohme Corp	RNA Interference Mediated Inhibition of the Nerve Growth Factor Beta Chain (NGFB) Gene Expression Using Short Interfering Nucleic Acid (siNA)
EP2411019A2 (en)	2009-03-27	2012-02-01	Merck Sharp&Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012521760A (ja)	2009-03-27	2012-09-20	メルク・シャープ・エンド・ドーム・コーポレイション	低分子干渉核酸（ｓｉＮＡ）を用いたアポトーシスシグナル調節キナーゼ１（ＡＳＫ１）遺伝子発現のＲＮＡ干渉媒介性阻害
EP2421834A1 (en)	2009-04-24	2012-02-29	Glaxo Group Limited	Pyrazole and triazole carboxamides as crac channel inhibitors
WO2010122089A1 (en)	2009-04-24	2010-10-28	Glaxo Group Limited	N-pyrazolyl carboxamides as crac channel inhibitors
SI2424864T1 (sl)	2009-04-30	2015-03-31	Glaxo Group Limited	Z oksazolom substituirani indazoli kot PI3-kinazni inhibitorji
EP2507231A1 (en)	2009-12-03	2012-10-10	Glaxo Group Limited	Indazole derivatives as pi 3 - kinase inhibitors
JP2013512879A (ja)	2009-12-03	2013-04-18	グラクソグループリミテッド	Ｐｉ３キナーゼの阻害剤としてのベンズピラゾール誘導体
EP2507226A1 (en)	2009-12-03	2012-10-10	Glaxo Group Limited	Novel compounds
WO2011110575A1 (en)	2010-03-11	2011-09-15	Glaxo Group Limited	Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
GB201007203D0 (en)	2010-04-29	2010-06-16	Glaxo Group Ltd	Novel compounds
WO2011143106A1 (en)	2010-05-10	2011-11-17	Gilead Sciences, Inc.	Bi - functional pyrazolopyridine compounds
EP2569285A1 (en) *	2010-05-10	2013-03-20	Gilead Sciences, Inc.	Bifunctional quinoline derivatives
ES2548036T3 (es)	2010-09-08	2015-10-13	Glaxosmithkline Intellectual Property Development Limited	Polimorfos y sales de N-[5-[4-(5-{[(2R,6S)-2,6-dimetil-4-morfolinil]metil}-1,3-oxazol-2-il)-1H-indazol-6-il]-2-(metiloxi)-3-piridinil]metanosulfonamida
JP5876051B2 (ja)	2010-09-08	2016-03-02	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＤｅｖｅｌｏｐｍｅｎｔＬｉｍｉｔｅｄ	インフルエンザウィルス感染の治療に使用するためのインダゾール誘導体
UY33597A (es)	2010-09-09	2012-04-30	Irm Llc	Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en)	2010-09-09	2012-03-15	Irm Llc	Compounds and compositions as trk inhibitors
WO2012035055A1 (en)	2010-09-17	2012-03-22	Glaxo Group Limited	Novel compounds
JP5795643B2 (ja)	2010-10-21	2015-10-14	グラクソグループリミテッドＧｌａｘｏＧｒｏｕｐＬｉｍｉｔｅｄ	アレルギー性状態、免疫性状態及び炎症性状態に作用するピラゾール化合物
WO2012052459A1 (en)	2010-10-21	2012-04-26	Glaxo Group Limited	Pyrazole compounds acting against allergic, inflammatory and immune disorders
GB201018124D0 (en)	2010-10-27	2010-12-08	Glaxo Group Ltd	Polymorphs and salts
US20130225524A1 (en) *	2010-11-05	2013-08-29	Deping Chai	Chemical Compounds
KR20140014184A (ko)	2011-02-25	2014-02-05	아이알엠 엘엘씨	Trk 억제제로서의 화합물 및 조성물
CA2829131C (en) *	2011-03-04	2018-11-20	Glaxosmithkline Intellectual Property (No.2) Limited	Amino-quinolines as kinase inhibitors
EP2683716A1 (en)	2011-03-11	2014-01-15	Glaxo Group Limited	Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
GB201104153D0 (en)	2011-03-11	2011-04-27	Glaxo Group Ltd	Novel compounds
TWI547494B (zh)	2011-08-18	2016-09-01	葛蘭素史克智慧財產發展有限公司	作為激酶抑制劑之胺基喹唑啉類
RU2610262C2 (ru) *	2011-11-03	2017-02-08	Мерк Шарп И Доум Корп.	ХИНОЛИНКАРБОКСАМИДНЫЕ И ХИНОЛИНКАРБОНИТРИЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ mGLuR2-НЕГАТИВНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ, КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ
TWI592417B (zh)	2012-09-13	2017-07-21	葛蘭素史克智慧財產發展有限公司	胺基喹唑啉激酶抑制劑之前藥
TW201425307A (zh)	2012-09-13	2014-07-01	Glaxosmithkline Llc	作為激酶抑制劑之胺基－喹啉類
AU2014212242B2 (en)	2013-02-01	2017-12-21	Pharma Cinq, Llc	Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity
WO2014128622A1 (en)	2013-02-21	2014-08-28	Glaxosmithkline Intellectual Property Development Limited	Quinazolines as kinase inhibitors
KR20160062179A (ko)	2013-10-17	2016-06-01	글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드	호흡기 질병의 치료를 위한 ｐｉ３ｋ 억제제
CA2925064A1 (en)	2013-10-17	2015-04-23	Glaxosmithkline Intellectual Property Development Limited	Pi3k inhibitor for treatment of respiratory disease
TW201625247A (zh)	2014-05-12	2016-07-16	葛蘭素史密斯克藍智慧財產權有限公司	用於治療傳染性疾病之醫藥組合物
JP6449482B2 (ja) *	2015-03-24	2019-01-09	シャンハイインリファーマシューティカルカンパニーリミティド	縮合環誘導体、その製造方法、中間体、薬学的組成物及び応用
GB201602527D0 (en)	2016-02-12	2016-03-30	Glaxosmithkline Ip Dev Ltd	Chemical compounds
US20190161480A1 (en)	2016-08-08	2019-05-30	Glaxosmithkline Intellectual Property Development Limited	Chemical Compounds
US20200085782A1 (en) *	2016-12-22	2020-03-19	Mavupharma, Inc.	Compositions and methods of enhancing or augmenting type i ifn production
GB201706102D0 (en)	2017-04-18	2017-05-31	Glaxosmithkline Ip Dev Ltd	Chemical compounds
GB201712081D0 (en)	2017-07-27	2017-09-13	Glaxosmithkline Ip Dev Ltd	Chemical compounds
CN111875594A (zh) *	2020-07-21	2020-11-03	中国药科大学	具有磷酸二酯酶4b抑制活性的吲唑杂环类化合物
TW202430172A (zh) *	2023-01-17	2024-08-01	大陸商瑞石生物醫藥有限公司	Ｐｄｅ４抑制劑、其製備方法及其在醫藥上的應用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE46886B1 (en)	1977-05-17	1983-10-19	Allen & Hanburys Ltd	Aminoalkyl-benzene derivatives
EP0048005A3 (de) *	1980-09-17	1983-01-19	ALFA-Institut für hauswirtschaftliche Produkt- und Verfahrens-Entwicklung GmbH	Vorrichtung zum Stapeln von Geschirr
GB9004781D0 (en)	1990-03-02	1990-04-25	Glaxo Group Ltd	Device
JPH04211661A (ja) *	1990-03-28	1992-08-03	Otsuka Pharmaceut Co Ltd	キノリン誘導体及び該誘導体を含有する抗潰瘍剤
US5214191A (en)	1990-05-22	1993-05-25	Cortech, Inc.	Oxidant sensitive and insensitive aromatic esters as inhibitors of human neutrophil elastase
MX9200299A (es)	1991-02-07	1992-12-01	Roussel Uclaf	Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
GB9127376D0 (en)	1991-12-24	1992-02-19	Wellcome Found	Amidino derivatives
JPH08508640A (ja)	1993-03-10	1996-09-17	スミスクライン・ビーチャム・コーポレイション	ヒト脳ホスホジエステラーゼ
FR2705346B1 (fr)	1993-05-18	1995-08-11	Union Pharma Scient Appl	Nouveaux dérivés de pipéridinyl thio indole, leurs procédés de préparation, compositions pharmaceutiques les contenant, utiles notamment comme antalgiques .
DK122693D0 (da)	1993-10-29	1993-10-29	Hempels Skibsfarve Fab J C	Marin struktur
ATE229001T1 (de)	1994-06-15	2002-12-15	Wellcome Found	Zwischenprodukte verwendbar in der herstellung von enzym-inhibitoren
WO1997044322A1 (en) *	1996-05-20	1997-11-27	Darwin Discovery Limited	Quinoline sulfonamides as tnf inhibitors and as pde-iv inhibitors
ATE227283T1 (de)	1996-07-13	2002-11-15	Glaxo Group Ltd	Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
WO1998013350A1 (en)	1996-09-25	1998-04-02	Zeneca Limited	Qinoline derivatives inhibiting the effect of growth factors such as vegf
GB9712761D0 (en) *	1997-06-17	1997-08-20	Chiroscience Ltd	Quinolines and their therapeutic use
MY117948A (en)	1997-01-13	2004-08-30	Glaxo Group Ltd	Nitride oxide synthase inhibitors.
CN1128790C (zh)	1997-12-22	2003-11-26	法玛西雅厄普约翰美国公司	用作抗病毒剂的4－羟基喹啉－3－甲酰胺和酰肼化合物
GB9811599D0 (en)	1998-05-30	1998-07-29	Glaxo Group Ltd	Nitric oxide synthase inhibitors
US6184226B1 (en)	1998-08-28	2001-02-06	Scios Inc.	Quinazoline derivatives as inhibitors of P-38 α
PT2253620E (pt)	1998-09-29	2014-04-15	Wyeth Holdings Llc	3-cianoquinolinas substituídas como inibidores de proteínas tirosinas quinases
AU763669B2 (en)	1998-09-29	2003-07-31	Wyeth Holdings Corporation	Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
AR028986A1 (es)	1999-02-23	2003-06-04	Smithkline Beecham Corp	USO DE UN INHIBIDOR DE PDE4 EN LA FABRICACIoN DE UNA PREPARACIoN DE LIBERACIoN CONTROLADA; FORMULACION DE LIBERACION CONTROLADA PARA EL TRATAMIENTO DE COPD, UN PROCEDIMIENTO PARA SU PREPARACIoN Y COMPOSICIoN FARMACÉUTICA
EP1161438B1 (en)	1999-03-15	2004-05-06	Abbott Laboratories	6-o-substituted macrolides having antibacterial activity
GB0008485D0 (en) *	2000-04-07	2000-05-24	Glaxo Group Ltd	Pharmaceutical compositions
US20020052312A1 (en)	2000-05-30	2002-05-02	Reiss Theodore F.	Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
AU8974901A (en)	2000-07-26	2002-02-05	Smithkline Beecham Plc	Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
US6576644B2 (en)	2000-09-06	2003-06-10	Bristol-Myers Squibb Co.	Quinoline inhibitors of cGMP phosphodiesterase
HUP0302302A2 (hu)	2000-09-29	2003-12-29	Glaxo Group Limited	Morfolin-acetamid-származékok gyulladásos betegségek kezelésére, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
GB0023918D0 (en)	2000-09-29	2000-11-15	King S College London	Antiparasitic compounds
US20020193393A1 (en)	2001-03-07	2002-12-19	Michel Pairet	Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
DE10110772A1 (de)	2001-03-07	2002-09-12	Boehringer Ingelheim Pharma	Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren
WO2002044166A1 (en)	2000-11-02	2002-06-06	Astrazeneca Ab	Substituted quinolines as antitumor agents
EP1337513A1 (en)	2000-11-02	2003-08-27	AstraZeneca AB	4-substituted quinolines as antitumor agents
GB0031179D0 (en)	2000-12-21	2001-01-31	Glaxo Group Ltd	Nitric oxide synthase inhibitors
GB0104422D0 (en)	2001-02-22	2001-04-11	Glaxo Group Ltd	Quinoline derivative
SE0101675D0 (sv)	2001-05-11	2001-05-11	Astrazeneca Ab	Novel composition
MY140679A (en)	2001-05-24	2010-01-15	Avanir Pharmaceuticals	Inhibitors of macrohage migration inhibitory factor and methods for identifying the same
PE20030008A1 (es)	2001-06-19	2003-01-22	Bristol Myers Squibb Co	Inhibidores duales de pde 7 y pde 4
JP2003005355A (ja)	2001-06-20	2003-01-08	Fuji Photo Film Co Ltd	電子線又はｘ線用ネガ型レジスト組成物
GB0118373D0 (en)	2001-07-27	2001-09-19	Glaxo Group Ltd	Novel therapeutic method
CA2464214C (en)	2001-10-22	2011-02-08	The Research Foundation Of State University Of New York	Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them
CA2468159A1 (en)	2001-11-27	2003-06-05	Merck & Co., Inc.	4-aminoquinoline compounds
WO2003048152A2 (en)	2001-12-05	2003-06-12	Tularik Inc.	Inflammation modulators
AU2003239302A1 (en)	2002-01-29	2003-09-02	Glaxo Group Limited	Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
DE10215316C1 (de)	2002-04-02	2003-12-18	Schering Ag	Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer
BR0311952A (pt)	2002-06-20	2005-04-19	Biovitrum Ab	Novos compostos úteis para o tratamento de obesidade, diabetes tipo ii e distúrbios do snc
WO2004067513A1 (en)	2003-01-27	2004-08-12	Oy Juvantia Pharma Ltd	Antagonists for alpha-2 adrenoceptors
JP2006519846A (ja)	2003-03-10	2006-08-31	シェーリング　コーポレイション	複素環式キナーゼインヒビター：使用および合成の方法
GB0322722D0 (en) *	2003-09-27	2003-10-29	Glaxo Group Ltd	Compounds
GB0322726D0 (en) *	2003-09-27	2003-10-29	Glaxo Group Ltd	Compounds

2004
- 2004-05-14 TW TW093113762A patent/TWI328009B/zh not_active IP Right Cessation
- 2004-05-19 PL PL08152215T patent/PL1944305T3/pl unknown
- 2004-05-19 AU AU2004240759A patent/AU2004240759B2/en not_active Ceased
- 2004-05-19 CA CA2526228A patent/CA2526228C/en not_active Expired - Fee Related
- 2004-05-19 KR KR1020057022135A patent/KR101144548B1/ko not_active Expired - Fee Related
- 2004-05-19 WO PCT/EP2004/005494 patent/WO2004103998A1/en active IP Right Grant
- 2004-05-19 ES ES08152215T patent/ES2374850T3/es not_active Expired - Lifetime
- 2004-05-19 MX MXPA05012466A patent/MXPA05012466A/es active IP Right Grant
- 2004-05-19 ES ES04733799T patent/ES2301993T3/es not_active Expired - Lifetime
- 2004-05-19 RU RU2005135016/04A patent/RU2335493C2/ru not_active IP Right Cessation
- 2004-05-19 PT PT04733799T patent/PT1633748E/pt unknown
- 2004-05-19 PT PT08152215T patent/PT1944305E/pt unknown
- 2004-05-19 PL PL04733799T patent/PL1633748T3/pl unknown
- 2004-05-19 DE DE602004012260T patent/DE602004012260T2/de not_active Expired - Lifetime
- 2004-05-19 AT AT08152215T patent/ATE529421T1/de active
- 2004-05-19 JP JP2006529889A patent/JP4625460B2/ja not_active Expired - Fee Related
- 2004-05-19 NZ NZ543554A patent/NZ543554A/en not_active IP Right Cessation
- 2004-05-19 DK DK04733799T patent/DK1633748T3/da active
- 2004-05-19 CN CN2004800206511A patent/CN1823063B/zh not_active Expired - Fee Related
- 2004-05-19 EP EP08152215A patent/EP1944305B1/en not_active Expired - Lifetime
- 2004-05-19 BR BRPI0410477-3A patent/BRPI0410477A/pt not_active IP Right Cessation
- 2004-05-19 DK DK08152215.3T patent/DK1944305T3/da active
- 2004-05-19 AT AT04733799T patent/ATE388148T1/de active
- 2004-05-19 AR ARP040101734A patent/AR044401A1/es unknown
- 2004-05-19 US US10/557,079 patent/US7566786B2/en not_active Expired - Fee Related
- 2004-05-19 SI SI200431802T patent/SI1944305T1/sl unknown
- 2004-05-19 EP EP04733799A patent/EP1633748B1/en not_active Expired - Lifetime
- 2004-05-19 SI SI200430691T patent/SI1633748T1/sl unknown
2005
- 2005-10-31 IS IS8110A patent/IS2581B/is unknown
- 2005-11-02 IL IL171726A patent/IL171726A/en not_active IP Right Cessation
- 2005-11-15 EG EGNA2005000730 patent/EG24774A/xx active
- 2005-11-16 CO CO05116284A patent/CO5700780A2/es active IP Right Grant
- 2005-11-16 NO NO20055421A patent/NO330754B1/no not_active IP Right Cessation
- 2005-11-17 ZA ZA200509319A patent/ZA200509319B/xx unknown
- 2005-11-21 MA MA28611A patent/MA27808A1/fr unknown
2006
- 2006-02-08 US US11/349,701 patent/US20070049570A1/en not_active Abandoned
- 2006-02-08 US US11/349,677 patent/US7572915B2/en not_active Expired - Fee Related
- 2006-09-07 HK HK06109975A patent/HK1092458A1/xx not_active IP Right Cessation
2008
- 2008-05-23 CY CY20081100534T patent/CY1108094T1/el unknown
- 2008-05-29 HR HR20080236T patent/HRP20080236T3/xx unknown
- 2008-08-21 HK HK08109372.1A patent/HK1118274A1/xx not_active IP Right Cessation
2009
- 2009-05-29 US US12/474,324 patent/US20090312325A1/en not_active Abandoned
2011
- 2011-12-20 HR HR20110957T patent/HRP20110957T1/hr unknown
2012
- 2012-01-11 CY CY20121100032T patent/CY1112232T1/el unknown

Also Published As

Publication number	Publication date
CN1823063A (zh)	2006-08-23
DE602004012260T2 (de)	2009-03-12
PT1944305E (pt)	2012-01-11
SI1944305T1 (sl)	2012-02-29
NO20055421D0 (no)	2005-11-16
JP4625460B2 (ja)	2011-02-02
US20070049570A1 (en)	2007-03-01
TWI328009B (en)	2010-08-01
AU2004240759A1 (en)	2004-12-02
IS8110A (is)	2005-10-31
IL171726A (en)	2013-07-31
DK1944305T3 (da)	2012-01-30
US20090312325A1 (en)	2009-12-17
CA2526228C (en)	2010-08-03
CA2526228A1 (en)	2004-12-02
DK1633748T3 (da)	2008-06-30
MA27808A1 (fr)	2006-03-01
HRP20080236T3 (en)	2008-06-30
TW200500358A (en)	2005-01-01
HK1092458A1 (en)	2007-02-09
CY1112232T1 (el)	2015-12-09
KR101144548B1 (ko)	2012-05-11
EP1944305B1 (en)	2011-10-19
PL1944305T3 (pl)	2012-03-30
US7572915B2 (en)	2009-08-11
PL1633748T3 (pl)	2008-07-31
AU2004240759B2 (en)	2010-03-04
ATE388148T1 (de)	2008-03-15
US20070142373A1 (en)	2007-06-21
AR044401A1 (es)	2005-09-14
PT1633748E (pt)	2008-05-20
ES2374850T3 (es)	2012-02-22
CO5700780A2 (es)	2006-11-30
MXPA05012466A (es)	2006-01-30
CN1823063B (zh)	2010-07-14
NO20055421L (no)	2005-12-20
EG24774A (en)	2010-08-19
SI1633748T1 (sl)	2008-08-31
NO330754B1 (no)	2011-07-04
JP2007501264A (ja)	2007-01-25
HK1118274A1 (en)	2009-02-06
KR20060015278A (ko)	2006-02-16
RU2005135016A (ru)	2006-06-27
EP1633748A1 (en)	2006-03-15
IS2581B (is)	2010-02-15
HRP20110957T1 (hr)	2012-01-31
US20060178416A1 (en)	2006-08-10
EP1944305A1 (en)	2008-07-16
CY1108094T1 (el)	2014-02-12
ES2301993T3 (es)	2008-07-01
ATE529421T1 (de)	2011-11-15
RU2335493C2 (ru)	2008-10-10
WO2004103998A1 (en)	2004-12-02
DE602004012260D1 (el)	2008-04-17
US7566786B2 (en)	2009-07-28
BRPI0410477A (pt)	2006-05-30
NZ543554A (en)	2008-09-26
EP1633748B1 (en)	2008-03-05

Publication	Publication Date	Title
HK1118274A1 (en)	2009-02-06	Quinoline derivatives as phosphodiesterase inhibitors
AP2048A (en)	2009-09-24	Diazepinoindole derivatives as kinase inhibitors
IL175947A0 (en)	2006-10-05	Novel quinoline derivatives
IL165515A0 (en)	2006-01-15	Bisindolyl-maleimid derivatives as kinase inhibitors
IL172132A0 (en)	2006-04-10	Thienopyridone derivatives as kinase inhibitors
HK1099297A1 (en)	2007-08-10	Quinoline derivatives for use as mycobacterial inhibitors
IL173381A0 (en)	2006-06-11	2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
HK1131055A1 (en)	2010-01-15	Novel benzylamine derivatives as cetp inhibitors
SG131944A1 (en)	2007-05-28	N3-substituted imidazopyridine-derivatives as c-kit inhibitors
IL172375A0 (en)	2009-02-11	Chinazoline derivatives as aurora kinase inhibitors
IL173001A0 (en)	2006-06-11	Nicotinamide derivatives useful as pde4 inhibitors
GB0317516D0 (en)	2003-08-27	Nicotinamide derivatives useful as PDE4 inhibitors
GB0317484D0 (en)	2003-08-27	Nicotinamide derivatives useful as pde4 inhibitors
GB0317482D0 (en)	2003-08-27	Nicotinamide derivatives useful as pde4 inhibitors
EG24415A (en)	2009-05-25	Quinoline derivatives
GB0317509D0 (en)	2003-08-27	Nicotinamide derivatives useful as PDE4 inhibitors
GB0317472D0 (en)	2003-08-27	Nicotinamide derivatives useful as PDE4 inhibitors
AU2003232362A8 (en)	2003-12-22	4-pyrazol-phenylalanine derivatives as ace-nep inhibitors
GB0205936D0 (en)	2002-04-24	Methylxanthine derivatives as Pl-3kinases inhibitors